FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider
Coral Springs, FL -- (ReleaseWire) -- 05/09/2013 --FinancialNewsMedia.com issues market news updates for today's pharmaceutical Companies: Crown Marketing (OTCQB: CWNM), Nuvilex, Inc. (OTCQB: NVLX), Elite Pharmaceuticals, Inc. (OTCQB: ELTP), Cannabis Science, Inc. (OTCQB: CBIS), and Merck (NYSE: MRK)
Headline News Alert: Crown Marketing Signs New Agreement for Medical Marijuana Financing Deal. Crown Marketing Inc. (OTCQB: CWNM) (“CWNM” or “Crown”) announced this morning that CWNM has executed a financial services agreement with a $100 Million Dollar Fund for the purposes of assisting medical marijuana producers secure financing for their commercial real estate needs and acquisitions. Crown Marketing will carry out these operations through a wholly owned subsidiary, Joint Venture Solutions Inc. (“Company”).
To Read the Entire Press Release, go to: http://www.financialnewsmedia.com/stock-investing-business-investing-news/featured-news.php?id=267
Nuvilex, Inc. (OTCQB: NVLX) News: Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that the market for the Nuvilex encapsulation delivery system could leap from the single digit billions in annual sales to tens of billions worldwide. Nuvilex is an international firm engaged in live-cell encapsulation technology to treat pancreatic cancer along with the development and study of the use of medical marijuana for the treatment of oncology patients. The Company's live-cell encapsulation drug delivery platform has already demonstrated that it can significantly improve the efficacy and safety results in mid-stage clinical trial studies in patients in advanced stages of pancreatic cancer.
To Read the Entire Press Release, go to: http://finance.yahoo.com/news/multiple-indications-equals-tens-billions-131000617.html
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) announced last month the issuance of U.S. Patent No. 8,425,933 entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" by the United States Patent and Trademark Office. This is the second issued U.S. patent covering Elite's abuse resistant technology for opioid products. Elite has additional patents pending in the U.S., Canada and Europe. "We are pleased to receive this second abuse resistant patent. The recent guidance's and actions by the FDA related to extended release opioids and specifically oxycodone demonstrates the FDA support for abuse resistant technologies. Opioid products incorporating abuse resistant technologies have become a public health priority and these recent actions appear to be a major step towards the FDA eventually requiring that all extended release opioids utilize these technologies.
Cannabis Science, Inc. (OTCQB: CBIS) announced in late April the initiation of preclinical development characterization of CS-TATI-I following the execution of contractual retention of vendor labs located in the Amsterdam Life Science Cluster. Under the direction of Richard Ogden, PhD, Chief Scientific Officer, and Christopher Meenan, MBA, MS, Executive Vice President of Product Manufacturing and Development, Cannabis Science, has begun initial preclinical pharmacological characterization, including pharmacokinetics, pharmacodynamics, concentration analysis, chemical structure characterization, and in vitro and in vivo extrapolation (IVIVE), as well as other essential studies that will be performed by contract manufacturing organizations utilizing proprietary strains of cannabinoids possessing properties characterized by peer reviewed literature indicating clinical attributes including inhibition of the genomic expression of HIV-associated Kaposi's Sarcoma (KS).
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, announced this week that the Biologics License Application (BLA) for its investigational ragweed pollen (Ambrosia artemisiifolia) sublingual allergy immunotherapy tablet has been accepted for review by the U.S. Food and Drug Administration (FDA). On March 27, Merck announced that the FDA had also accepted the BLA for its investigational Timothy grass pollen (Phleum pratense) sublingual allergy immunotherapy tablet. Merck expects the FDA’s review for both to be completed in the first half of 2014. The BLA for Merck’s investigational ragweed pollen sublingual allergy immunotherapy tablet is supported by five studies evaluating the efficacy and safety of the tablet in adults, 18 years of age or older, with ragweed induced allergic rhinitis (with or without conjunctivitis).
To Read the Entire Press Release, go to: http://finance.yahoo.com/news/merck-announces-fda-acceptance-biologics-123000141.html
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.
FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
Company: FN Media Group, LLC
Contact email: email@example.com
U.S. Phone: 1(954)345-0611
Source: FN Media Group